Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Ikeda, Ken ^a   Iwasaki, Yasuo ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NORPHENAZONE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MOUSE; MUSCLE ATROPHY; MUSCLE CONTRACTURE; MUSCLE WEAKNESS; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; ASTROCYTE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; MUSCLE CONTRACTION; MUSCLE STRENGTH; PATHOLOGY; RANDOMIZATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIPYRINE; ASTROCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FREE RADICAL SCAVENGERS; INJECTIONS, INTRAPERITONEAL; MICE; MUSCLE CONTRACTION; MUSCLE STRENGTH; RANDOM ALLOCATION;

EID: 84949035818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140316     Document Type: Article

References (32)

1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American educational tool for neurologists. Stroke 2007; 38(5):1655-711. PMID: 17431204
2. Kikuchi K, Kawahara K, Tancharoen S, Matsuda F, Morimoto Y, Ito T, et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 2009; 329(3):865-74. doi: 10.1124/jpet.108.149484 PMID: 19293391
3. Kikuchi K, Tancharoen S, Matsuda F, Biswas KK, Ito T, Morimoto Y, et al. Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 2009; 390(4):1121-5. doi: 10.1016/j.bbrc.2009.09.015 PMID: 19737535
4. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger for treatment of cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2006; 1(1):85-93. PMID: 18221078
5. Kikuchi K, Kawahara K, Uchikado H, Miyagi N, Kuramoto T, Miyagi T, et al. Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Exp Ther Med 2011; 2 (5):771-5. PMID: 22977573
6. Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15(7-8):610-7. doi: 10.3109/21678421.2014.959024 PMID: 25286015
7. Falconer DS. Wobbler (wr). Mouse News Lett 1956; 15:23.
8. Duchen LW, Strich SJ. An hereditary motor neurone disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'. J Neurol Neurosurg Psychiatry 1968; 31(6):535-42. PMID: 5709840
9. Mitsumoto H, Bradley WG. Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron. Brain 1982; 105(Pt 4):811-34. PMID: 7139256
10. Moser JM, Bigini P, Schmitt-John T. The wobbler mouse, an ALS animal model. Mol Genet Genomics 2013; 288(5-6):207-29. doi: 10.1007/s00438-013-0741-0 PMID: 23539154
11. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994; 265(5175):1107-10. PMID: 8066451
12. Ikeda K, Kinoshita M, Iwasaki Y, Tagaya N, Shiojima T. Lecithinized superoxide dismutase retards wobbler mouse motoneuron disease. Neuromuscul Disord 1995; 5(5):383-90. PMID: 7496172
13. Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM, et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995; 37 (4):505-11. PMID: 7717687
14. Ikeda K, Iwasaki Y, Kinoshita M. Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse. J Neurol Sci 1998; 160(1):9-15. PMID: 9804111
15. Ikeda K, Iwasaki Y, Kinoshita M. Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(3):207-12. PMID: 11464954
16. Ikeda K, Iwasaki Y, Kinoshita M, Marubuchi S, Ono S. T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease. Brain Res 2000; 858(1):84-91. PMID: 10700601
17. Hirayama T, Yoshii Y, Kawabe K, Ikeda K. Zonisamide treatment delays motor neuron degeneration and astrocyte proliferation in wobbler mice. J Neurology Res 2011; 1(4):139-44.
18. Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci 2015; 354(1-2):70-4. doi: 10.1016/j.jns.2015.04. 052 PMID: 25982504
19. Quenneville NR, Chao TY, McCaffery JM, Conibear E. Domains within the GARP subunit Vps54 confer separate functions in complex assembly and early endosome recognition. Mol Biol Cell 2006; 17 (4):1859-70. PMID: 16452629
20. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001; 29(2):160-5. PMID: 11586297
21. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75(5):822-31. PMID: 15372378
22. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465(7295):223-6. doi: 10.1038/nature08971 PMID: 20428114
23. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68(5):857-64 doi:10. 1016/j.neuron.2010.11.036 PMID: 21145000
24. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006; 67(6):1074-7. PMID: 16807408
25. Dennis JS, Citron BA. Wobbler mice modeling motor neuron disease display elevated transactive response DNA binding protein. Neuroscience 2009; 158(2):745-50. doi: 10.1016/j.neuroscience.2008. 10.030 PMID: 19013502
26. Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis 2014; 62:218-32. PMID: 24141020
27. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008; 213 (2):448-55. doi: 10.1016/j.expneurol.2008.07.017 PMID: 18718468
28. Aoki M, Warita H, Mizuno H, Suzuki N, Yuki S, Itoyama Y. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res 2011; 1382: 321-5. PMID: 21276427
29. Aoyama T, Hida K, Kuroda S, Seki T, Yano S, Shichinohe H, et al. Edaravone (MCI-186) scavenges reactive oxygen species and ameliorates tissue damage in the murine spinal cord injury model. Neurol Med Chir 2008; 48(12):539-45.
30. Suzuki K, Kazui T, Terada H Umemura K, Ikeda Y, Bashar AH, et al. Experimental study on the protective effects of edaravone against ischemic spinal cord injury. J Thorac Cardiovasc Surg 2005; 130 (6):1586-92. PMID: 16308003
31. Takahashi G, Sakurai M, Abe K, Itoyama Y, Tabayashi K. MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits. J Thorac Cardiovasc Surg 2003; 126(5):1461-6. PMID: 14666020
32. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014; 13(11):1127-38. doi: 10.1016/S1474-4422 (14)70129-2 PMID: 25316019